By Brian Dolan
Reposted from mobihealthnews
The University of Southern California’s Chief of Cardiology and Executive Director of USC’s Center for Body Computing, Dr. Leslie Saxon authored a study set to be published in the medical journal, Circulation. The study followed more than 100,000 patients across the US. who have implanted cardiac devices — cardiac resynchronization therapy (CRT) devices and implantable cardioverter-defibrillator (ICD) devices. The study examined survival rates among those patients with wireless-enabled devices and those with no wireless-enabled tracking.
The study concluded that those patients whose ICD included wireless-enabled tracking faced half (50 percent) the mortality rate than those who only received follow-up care at device clinics. MobiHealthNews had a chance to interview Dr. Saxon about the study results.
MobiHealthNews: With efficacy studies today it seems like the press pans the entire connected health industry when there’s a failure and celebrates the entire industry when a study proves to be a success. How would you contextualize the results of this study? Who do these results effect?
Saxon: This study’s results effect hundreds of thousands of people today. The type of implantable device we looked at is going into upwards of 15,000 to 20,000 patients a month. These are patients that have incurred very high costs within the medical care system. That’s because they have a very expensive piece of hardware inside them — either a defibrillator or re-synchronization device — because means they have heart failure. Heart failure is the number one diagnosis for patients admitted and discharged from hospitals today. It is extremely expensive to treat this type of advanced heart failure because the re-hospitalization rate is upwards of 40 percent.